Nasal Carrying by Staphylococcus Aureus ST398 Strains in Community and Hospital Settings
CONASA 398
1 other identifier
observational
2,000
1 country
1
Brief Summary
The aim of this study was to compare the prevalence of nasal carrying of SA ST398 strains in community and hospital settings, identify the factors associated with colonization of SA ST398, determine the distribution of imported and acquired cases among SA ST398 hospital cases and characterize the genetic structure of the ST398 SA population involved in colonization.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Apr 2019
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
February 21, 2019
CompletedFirst Posted
Study publicly available on registry
March 11, 2019
CompletedStudy Start
First participant enrolled
April 1, 2019
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 1, 2020
CompletedStudy Completion
Last participant's last visit for all outcomes
September 1, 2020
CompletedMarch 11, 2019
February 1, 2019
1 year
February 21, 2019
March 8, 2019
Conditions
Outcome Measures
Primary Outcomes (1)
Number of patients nasal carrying of SA ST398 strains in community and hospital settings
Number of patients with SA ST398 positive nasal swab in community will be compared with number of patients with SA ST398 positive nasal swab in hospital
One day
Secondary Outcomes (3)
Number of patietns with specific Clinical and demographic data associated with nasal carrying of SA ST398
One day
Number of patients with SA ST398 positive nasal swab to seven days of hospitalization
7 days
Number of virulence gene in SA ST 398 strains
One day
Study Arms (2)
Hospitalized patients
Within 48 hours of admission to participating departments, all patiens will be included. A nasal swab will be performed within the first 48 hours and on the 7th day.
Community patients
People coming to donate blood in "Etablissement Français du Sang" will be included and a nasal swab will be performed
Interventions
In hospitalized patiens, a nasal swab will be performed within the first 48 hours and on the 7th day. In community patient, only one swab will be performed
Eligibility Criteria
For community patients : All patients presenting for blood donation will be included For hospitalized patients, all patients hospitalized less than 48h in a service participating to the study will be enrolled
You may qualify if:
- the selection criteria for blood donation
- age ≥ 18 years old
- No refusal of the person
You may not qualify if:
- None
- For hospitalized patients :
- age ≥ 18 years old
- hospitalization in one of the services participating in the study
- no refusal of the person
- None
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
CHU de Besançon
Besançon, 25000, France
Biospecimen
Nasal swab
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
February 21, 2019
First Posted
March 11, 2019
Study Start
April 1, 2019
Primary Completion
April 1, 2020
Study Completion
September 1, 2020
Last Updated
March 11, 2019
Record last verified: 2019-02
Data Sharing
- IPD Sharing
- Will not share